NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/02/2026
Back to search
Official data from USPTO
PINOVA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PINOVA THERAPEUTICS
ST13
US500000097135396Class
5, 42, 44
Filing
97135396
Registration
8285284
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
06/02/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
11/19/2021
Registration date
06/02/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/02/2026
Last transaction
06/02/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/03/2025
First use in commerce
06/03/2025
Drawing code
4
Owner type
03
Owner location
Bethesda, MD, US
Examiner
ATTANG, UDEME U
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Pocket Naloxone Corp.
Representatives
Spencer Wolff Esquire Spencer Wolff Law PC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations for the treatment of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapy side effectssmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty
Class 42
scientific research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty; pharmaceutical research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty; pharmaceutical research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty; pharmaceutical research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty
Class 44
medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty
Publications
History of USPTO decisions and trademark events.
50 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/11/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/11/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/11/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/06/2026
IUAF
USE AMENDMENT FILED
10/17/2025
EISU
TEAS STATEMENT OF USE RECEIVED
10/17/2025
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
10/17/2025
NREV
NOTICE OF REVIVAL - E-MAILED
10/17/2025
PETG
PETITION TO REVIVE-GRANTED
10/17/2025
PROA
TEAS PETITION TO REVIVE RECEIVED
10/17/2025
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
10/13/2025
ABN6
ABANDONMENT - NO USE STATEMENT FILED
10/13/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/20/2025
EX3G
SOU EXTENSION 3 GRANTED
02/19/2025
EXT3
SOU EXTENSION 3 FILED
02/19/2025
EEXT
SOU TEAS EXTENSION RECEIVED
02/19/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/21/2024
EX2G
SOU EXTENSION 2 GRANTED
08/21/2024
EXT2
SOU EXTENSION 2 FILED
08/21/2024
EEXT
SOU TEAS EXTENSION RECEIVED
08/21/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/05/2024
EX1G
SOU EXTENSION 1 GRANTED
03/02/2024
EXT1
SOU EXTENSION 1 FILED
03/02/2024
EEXT
SOU TEAS EXTENSION RECEIVED
03/02/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/18/2023
PUBO
PUBLISHED FOR OPPOSITION
07/18/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/28/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/14/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/14/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/14/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/14/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/11/2023
GNRT
NON-FINAL ACTION E-MAILED
04/11/2023
CNRT
NON-FINAL ACTION WRITTEN
04/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/28/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/28/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/31/2022
GNRT
NON-FINAL ACTION E-MAILED
08/31/2022
CNRT
NON-FINAL ACTION WRITTEN
08/31/2022
DOCK
ASSIGNED TO EXAMINER
08/30/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/24/2021
NWAP
NEW APPLICATION ENTERED
11/23/2021
Continuous trademark protection
Get notified about every new filing that threatens PINOVA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.